跳至主要内容
临床试验/NCT03385382
NCT03385382已完成不适用

Macular Thickness and Vessel Density Changes After Dexamethasone Implant and Ranibizumab Intravitreal Injection in Diabetic Macular Edema: 6-month Follow-up

G. d'Annunzio University0 个研究点目标入组 40 人开始时间: 2016年12月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
主要终点
Central macular thickness

研究概览

简要总结

Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University "G. d'Annunzio", Chieti-Pescara, Italy.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
19 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years old
  • BCVA greater than 0.5 LogMAR in the study eye at baseline examination
  • Presence of recent DME
  • CMT > 300µm as measured using the SD-OCT at the baseline examination

排除标准

  • Any previous ocular surgery in the last 6 months
  • Laser treatments
  • Prior ocular trauma
  • Retinal vascular diseases
  • Vitreo-retinal interface diseases
  • Medium lens opacities (according to Lens Opacities Classification System)

研究组 & 干预措施

Dexamethasone group

Patients with diabetic macular edema receiving dexamethasone

干预措施: Dexamethasone intravitreal implant 0.7 mg (Drug)

ranibizumab

Patients with diabetic macular edema receiving ranibizumab

干预措施: Ranibizumab Injection (Drug)

结局指标

主要结局

Central macular thickness

时间窗: 6 months

Decrease of macular thickness

次要结局

  • visual acuity(6 months)

研究者

发起方
G. d'Annunzio University
申办方类型
Other
责任方
Principal Investigator
主要研究者

LISA TOTO

Researcher

G. d'Annunzio University

相似试验